Simple Summary Antibodies directed at so-called immune checkpoint molecules represent a
substantial improvement in cancer therapy. These biological reagents highlight the exquisite …

The invention is directed an anti-CCR5 antibody which com prises (i) two light chains, each
light chain comprising the expression product of a plasmid designated pVK: Hu PRO140-VK …

T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited
options of efficient therapies. Most patients are refractory to chemotherapies and despite …

We previously described the in vitro characteristics of the potent and selective CCR1
antagonist, CP-481,715. In addition to being selective for CCR1 vs other chemokine …

Originally, chemokines and their G‐protein‐coupled receptors were described to regulate
multiple physiological functions, particularly tissue architecture and compartment‐specific …

The human CC chemokine receptor 8 (CCR8) is a promising drug target for cancer
immunotherapy and autoimmune disease. Besides human and viral chemokines, previous …

Here, we report that tumor cells from some patients (23.8%) with Hodgkin lymphoma (HL)
are positive for CC chemokine receptor 4 (CCR4). We therefore tested the chimeric anti …

Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell
leukemia and lymphoma, but still have many challenges in their use for treating T cell …

Introduction: KW-0761 is a defucosylated humanized IgG1 monoclonal antibody against CC
chemokine receptor 4 (CCR4). Previous studies revealed that CCR4 was over-expressed on …

INTRODUCTION: Chemokines are regulated by a family of 'atypical'chemokine receptors,
D6, DARC and CCX-CKR, each of which efficiently internalizes its cognate chemokine …